BioMarin Completes Enrollment of Phase 2 Clinical Study of 6R-BH4 in Poorly Controlled Hypertension
NOVATO, Calif., Sept. 20 /PRNewswire-FirstCall/ — BioMarin Pharmaceutical Inc. ( Nachrichten ) (Nasdaq and SWX: BMRN) announced today that it has completed enrollment of the Phase 2 clinical study of 6R-BH4 for the treatment of poorly controlled hypertension.
